UK specialty pharma company Diurnal (AIM: DNL) has announced the appointment of Richard Bungay as chief financial officer (CFO).
Starting on Monday, Mr Bungay will take over from Ian Ardill, who is leaving to pursue other business opportunities, the company said in a statement.
"Richard’s experience will be invaluable as Diurnal strides towards realizing its ambition of becoming a world-leading endocrinology specialty pharma company"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze